Disease Activity and Maternal–fetal Outcomes in Pregnant Women With Prolactinoma: A Systematic Review and Meta-analysis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorEndocrine Division (SEMPR)-
Autor(es): dc.creatorBandeira, Diego Barata-
Autor(es): dc.creatorAlves, Letícia Santana-
Autor(es): dc.creatorGlezer, Andrea-
Autor(es): dc.creatorBoguszewski, Cesar Luiz-
Autor(es): dc.creatordos Santos Nunes-Nogueira, Vania-
Data de aceite: dc.date.accessioned2025-08-21T19:19:25Z-
Data de disponibilização: dc.date.available2025-08-21T19:19:25Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2025-04-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1210/clinem/dgae821-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/299860-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/299860-
Descrição: dc.descriptionContext: Women with prolactinoma are usually infertile but can conceive after surgery or treatment with dopamine agonists. Objective: To evaluate the impact of pregnancy in prolactinoma's natural course and in maternal–fetal outcomes. Data Sources: MEDLINE, EMBASE, LILACS, and CENTRAL. Study Selection: Observational studies that included at least 3 pregnant women with prolactinoma. Data Extraction: Two independent reviewers selected studies, assessed the risk of bias, and extracted data from the included studies. Data Synthesis: Fifty-two studies were included, involving 2544 pregnancies in 1928 women. Stata Statistical Software 18 was used for proportional meta-analyses. The overall frequency of pregnant women on dopamine agonist treatment at conception was 97% and for either continuing or resuming treatment during pregnancy was 6%. The overall frequency of miscarriage was 10% (95% CI, 8-12), 3% for prematurity (95% CI, 2-5), 4% for symptomatic tumor growth during pregnancy (95% CI, 2-8), 4% for visual impairment (95% CI, 2-7), 6% for headache (95% CI, 4-9), and 4% for development of gestational diabetes (95% CI, 3-7). The overall frequency of congenital malformations was 2% (95% CI, 1-4), 2% for perinatal mortality (95% CI, 1-2), and 6% for low birth weight (95% CI, 3-9). Moreover, prolactinoma's size is a significant modifier for visual impairment. Conclusion: Pregnancy in women with prolactinoma is safe in relation to fetal and maternal outcomes with low frequencies of miscarriage, prematurity, symptomatic growth, visual impairment, headache, congenital malformations, perinatal mortality, and low birth weight.-
Descrição: dc.descriptionDepartment of Internal Medicine São Paulo State University (UNESP) Medical School Botucatu-
Descrição: dc.descriptionNeuroendocrine Unit Division of Endocrinology and Metabolism Hospital das Clínicas University of Sao Paulo Medical School-
Descrição: dc.descriptionDepartment of Internal Medicine Federal University of Parana Endocrine Division (SEMPR)-
Descrição: dc.descriptionDepartment of Internal Medicine São Paulo State University (UNESP) Medical School Botucatu-
Formato: dc.formate1241-e1251-
Idioma: dc.languageen-
Relação: dc.relationJournal of Clinical Endocrinology and Metabolism-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectdopamine agonist-
Palavras-chave: dc.subjectmeta-analysis-
Palavras-chave: dc.subjectpregnancy-
Palavras-chave: dc.subjectprolactinoma-
Palavras-chave: dc.subjectsystematic review-
Título: dc.titleDisease Activity and Maternal–fetal Outcomes in Pregnant Women With Prolactinoma: A Systematic Review and Meta-analysis-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.